In conclusion, we demonstrated that a hepatokine, soluble EGFR, and an adipokine, adipsin, were correlated with distinct aspects of insulin resistance in human T2DM subjects, suggesting that soluble EGFR can be used as a biomarker for hepatic insulin resistance and hyperglycemia and that adipsin can be used as a biomarker for fat insulin resistance and visceral fat accumulation. This evidence concerns the gene CFD and type 2 diabetes mellitus.